115 results
Page 3 of 6
8-K
EX-99.1
qkne6wdrqh1u8w hc77
17 Apr 23
Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol
4:06pm
8-K
EX-99.1
zoechm1608u3fez3
30 Mar 23
Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights
4:07pm
8-K
EX-99.1
340fi vc50
10 Nov 22
Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
4:29pm
8-K
EX-99.1
jtw3 u942b
8 Nov 22
Completion of Acquisition or Disposition of Assets
8:40am
8-K
EX-99.1
imk2vafc1z91ugbs
12 Oct 22
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering
9:00am
8-K
EX-4.3
au3 5m9ox
12 Oct 22
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering
9:00am
8-K
1ygg28a
12 Oct 22
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering
9:00am
8-K
EX-99.2
92hd qnm3e
12 Oct 22
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering
9:00am
424B4
7nh21gqhg4uhcppyb
11 Oct 22
Prospectus supplement with pricing info
8:27am
FWP
xuxc7
6 Oct 22
Free writing prospectus
4:05pm
8-K
EX-99.1
478n lrm86gn
22 Sep 22
Material Modifications to Rights of Security Holders
4:32pm